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Abstract
Background: Enhanced cardiovascular secondary preventive follow-up is needed to improve adherence to
recommended low-density lipoprotein cholesterol (LDL-C) and blood pressure (BP) levels. Patients with diabetes
mellitus (DM) or chronic kidney disease (CKD) have a high risk of recurrent events. Secondary prevention is
therefore essential in these patients.
Methods: Patients with acute coronary syndrome, stroke, or transient ischemic attack were randomized to
nurse-based telephone follow-up (intervention) or usual care (control). LDL-C and BP were measured at 1 month
(baseline) and 12 months post-discharge. Intervention patients with above-target values at baseline received
medication titration to achieve treatment goals. Values measured for control patients were given to the patient’s
general practitioner for assessment.
Results: The final analyses included 225 intervention and 215 control patients with DM or CKD. Among patients with
above-target baseline values, the following 12-month values were recorded for intervention and control patients,
respectively: LDL-C, 2.2 versus 3.0 mmol/L (p < 0.001); and median systolic BP (SBP), 140 versus 145 mmHg (p = 0.26).
Among patients with above-target values at baseline, 52.3 % of intervention patients reached target LDL-C values at
12 months versus 21.3 % of control patients (absolute difference of 30.9 %, 95 % CI 16.1 to 43.8 %), and there was a
non-significant trend of more intervention patients reaching target SBP (49.4 % versus 36.8 %; absolute difference of
12.6 %, 95 % CI −1.7 to 26.2 %).
Conclusions: Cardiovascular secondary prevention with nurse-based telephone follow-up was more effective than
usual care in improving LDL-C levels 12 months after discharge for patients with DM or CKD.
Trial registration: ISRCTN registry; ISRCTN96595458 (date of registration 10 July 2011) and ISRCTN23868518 (date of
registration 13 May 2012).
Keywords: Acute coronary syndrome, Myocardial infarction, Stroke, Transient ischemic attack, Diabetes mellitus,
Chronic renal insufficiency, Secondary prevention, Cardiovascular disease
Background
Following an acute coronary syndrome (ACS) or stroke
there is a high risk of recurrent events. A population based
study of patients with ischemic stroke found that the cu-
mulative five year risk of MI, stroke or vascular event was
29 % [1]. Furthermore, data from Swedish Web-system for
Enhancement and Development of Evidence-based care in
Heart disease Evaluated According to Recommended
Therapies (SWEDEHEART) show that 13 % of the patients
are readmitted for a cardiac disease during the year follow-
ing a myocardial infarction and 4 % suffer an ischemic
stroke within one year [2, 3]. Morbidity and case fatality
after an ACS or stroke can be reduced by secondary pre-
ventive treatments that lower lipid levels and blood pres-
sure (BP) [4]. However, implementation of such treatments
has been unexpectedly difficult, with low proportions of
patients reaching the recommended blood lipid levels and
BP [5–7]. In EUROASPIRE IV patients with an ACS or
who were revascularized with percutaneous coronary
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intervention or coronary artery bypass grafting were exam-
ined between six months and three years after the qualify-
ing event. Approximately 80–90 % of the patients received
a blood pressure lowering drug and a statin, but of those
receiving treatment only 57 and 21 % reached target levels
for BP and low-density lipoprotein cholesterol (LDL-C),
respectively [7]. Various organizational strategies have
been evaluated for improving secondary preventive care in
patients with established cardiovascular disease (CVD),
including patient education, physician education, pre-
booked doctor appointments, etc. However, most investi-
gated strategies have not effectively reduced risk factors
[8, 9]. Some data suggest that telephone-based follow-up
improves risk factor control [10].
Diabetes mellitus (DM) and chronic kidney disease
(CKD) are common comorbidities in patients with estab-
lished CVD. In a population of Medicare beneficiaries of
65 years of age or older in the United States, DM was found
in approximately 40 % of the patients with ischemic heart
disease or stroke and CKD was found in 30–35 % of the pa-
tients [11]. Moreover, patients with DM or CKD have a
worse prognosis after a CVD. For example, one study
showed that the hazard ratio of death for DM patients
compared to non-DM patients one year after an ACS was
increased (1.33; 95 % confidence interval 1.20–1.48) and a
pooled analysis of community-based cohorts showed that
over 60 % of the patients with established CVD and CKD
suffered a MI, fatal coronary heart disease, stroke, or died
during a 10-year time period, compared to approximately
35 % of the non-CKD patients [12, 13]. While the age-
standardized death rates after an ACS or stroke have
decreased over recent years [14], the prevalences of DM
and CKD are increasing [15, 16]. Thus, there is a potentially
growing population with CVD in combination with DM
and/or CKD. These patients have a very high risk of recur-
rent events and secondary prevention is therefore essential.
The Nurse-Based Age-Independent Intervention to
Limit Evolution of Disease (NAILED) ACS and NAILED
stroke risk factor trials are ongoing randomized controlled
trials that aim to improve secondary prevention after
ACS, stroke, and transient ischemic attack (TIA) through
nurse-based telephone follow-up of modifiable risk fac-
tors. Considering the importance of secondary prevention,
we performed the present study to investigate the effects
of follow-up according to the NAILED trial in a high-risk
patient population with DM or CKD. We hypothesized
that compared to usual care, the NAILED follow-up
would more effectively improve LDL-C levels and BP at
12 months after an ACS, stroke, or TIA.
Method
The rationale and the open, population-based, random-
ized controlled design of the NAILED trials have been
previously described [17, 18]. In brief, all patients
hospitalized at Ostersund Hospital with a diagnosis of
myocardial infarction, unstable angina, stroke, or TIA
were assessed for inclusion. Ostersund Hospital is the only
hospital in the county of Jamtland, Sweden, and has a
rural catchment area with a population of approximately
125,000 inhabitants. Study nurses identified eligible pa-
tients with the physical and mental capacity to communi-
cate by telephone. Patients suffering from deafness,
aphasia, dementia, or severe (often terminal) diseases were
not included. Participants in other ongoing trials were also
excluded. All eligible patients were informed about the
study and asked to sign a written informed consent. Those
who agreed to participate were randomized to interven-
tion or control in a 1:1 ratio. The random allocation se-
quence was computer generated in blocks of four and
stratified for sex and type of ACS (unstable angina or
myocardial infarction) for ACS patients. For patients with
stroke or TIA the random sequence was generated in
blocks of four and was stratified for sex and for degree of
disability (modified Rankin Scale <3 or ≥3).
This study was approved by the Regional Ethics Com-
mittee, Umea University 28 October 2009 (reference
number Dnr-09-142M).
Patient characteristics, including medical history, were
recorded during the initial hospitalization. At 1 month
after discharge, baseline measurements of blood lipids
and BP were performed by a health care professional at
the patients’ closest health care facility and reported to
the study team. Corresponding follow-up measurements
were performed at 12 months after discharge. Shortly
after the measurements of blood lipids and BP, a study
nurse contacted participants in both study groups by
telephone and interviewed them about their well-being
and adherence to medical treatment.
In the control group, LDL-C and BP values were for-
warded directly to the patient’s general practitioner (GP) for
assessment, without further action from the study team.
The patients in the control group received secondary pre-
ventive care according to local standard management. Sec-
ondary preventive treatment was generally initiated in-
hospital and thereafter, the patients’ GPs held primary
responsibility for their care. The standard of care for DM
patients is, according to local guidelines, a yearly visit to
their GP and a yearly visit to a nurse. During the visits a risk
factor assessment and intervention regarding established
risk factors for CVD is performed. The secondary prevent-
ive management of CKD patients does not differ from the
overall CVD population. Patients in both study groups
could at any time book an appointment with their GP.
For patients randomized to intervention, if they had
not reached the target LDL-C level and/or BP their
medication was titrated according to guidelines. The ini-
tial target value for LDL-C level was <2.5 mmol/L. On
31 March, 2013, the local guidelines for diabetic patients
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changed such that the target level was <1.8 mmol/L.
Throughout the trial period, the target BP value was
<140/90 mmHg. Tests were repeated within approxi-
mately 4 weeks. If necessary, medication was further
titrated until target values were reached or no further
changes were considered appropriate. Decisions regard-
ing titration and medication were made by a study
physician.
The present analysis included patients with DM or
CKD, who were admitted between 1 January, 2010 and
30 June, 2013 and who received a 12-month follow-up
call. Patients were considered to have DM if they re-
ceived glucose-lowering medication or dietary treatment
at discharge from their initial hospitalization. During
hospitalization, a creatinine value was registered and an
estimated glomerular filtration rate (eGFR) was calcu-
lated using the Chronic Kidney Disease Epidemiology
Collaboration (CKD-EPI) creatinine equations [19]. Pa-
tients were assumed to be Caucasian. An eGFR < 60 mL/
min/1.73 m2 was considered to indicate the presence of
CKD [20].
Outcomes
The primary outcome in the present analysis was to deter-
mine the difference in LDL-C and systolic blood pressure
(SBP) between patients in the two groups at 12 months
follow-up, before any medication titrations. The differences
in diastolic blood pressure (DBP) and proportions of
reached target values between the groups were secondary
outcomes. Exploratory data analyses with between-group
comparison of risk factor values and proportion of patients
within target values were performed separately for patients
with DM and CKD.
Availability of data
Deposition of patient level data in a public repository
was not specified in the study protocol as approved by
the ethics committee before the study started. Patient
level data will be available on request, provided that an
approval from the Regional Ethics Committee is given.
Statistics
The results are presented as median and percentiles for
continuous variables, and as percentages for categorical
variables. To analyse the effects of the intervention, risk
factor values and the proportion of achieved target values
at 12 months were analysed separately among patients
who did and did not meet risk factor target values at
baseline. To assess between-group differences, the Mann–
Whitney U-test was used for continuous variables and
Pearson’s χ2 test for categorical variables. Within-group
changes from baseline to 12-month follow-up were exam-
ined using the Wilcoxon signed-rank test.
Power analysis showed that study groups of approxi-
mately 80 participants were required to detect between-
group differences of 0.4 mmol/L in mean LDL-C, of
8 mmHg in mean SBP, and of 20 % in the proportions of
reached target values (alpha 0.05, two-tailed, power
80 %). Subjects with missing values were excluded from
the analysis. The Bonferroni technique was used to
adjust the alpha value because multiple comparisons
were performed within each group. After adjustment an
alpha value of 0.01 was considered significant in the risk
factor value analyses. Statistical analyses were performed
using SPSS 20.0 software.
Results
Between January 2010 and June 2013, 1511 ACS, stroke,
or TIA patients were included in the study. Of these
subjects, 758 (33.9 % [257/758] with DM or CKD) were
randomized to the intervention group and 753 (33.6 %
[253/753] with DM or CKD) to the control group. The
final analyses included 225 patients with DM or CKD in
the intervention group and 215 patients in the control
group (Fig. 1). Table 1 shows the patients’ in-hospital
characteristics. The groups were well matched except
for that fewer patients in the intervention group
received lipid-lowering treatment at admission (40.9 %
versus 52.6 %). Thirty-five patients in the intervention
group and 36 patients in the control group had both
DM and CKD.
Risk factor values at 12 months
The baseline median values for LDL-C, SBP, and DBP,
for patients not meeting target values were similar be-
tween the intervention and control groups (Table 2). At
the 12-month follow-up, both groups showed significant
decreases in these risk factor values compared to base-
line. LDL-C levels at 12 months were significantly lower
in the intervention group (2.2 mmol/L) compared to the
control group (3.0 mmol/L) (p < 0.001). We observed
a non-significant trend towards a lower SBP value in
the intervention group (140 mmHg) compared to in
the control group (145 mmHg) (p = 0.26) (Table 2).
Additional file 1 shows the corresponding data for the
patients who met target values at baseline. Among these
patients, the risk factor values generally increased between
baseline and 12 months and there were no significant
between-group differences.
Proportions of patients who achieved target values at
12 months
At baseline, the target LDL-C level was met by 60.8 %
(135/222) in the intervention group and by 62.7 % (131/
209) of the control group (absolute difference of 1.9 %,
95 % CI −7.2 to 10.9 %), target SBP by 60.3 % (135/224) of
the intervention group and 55.8 % (120/215) of controls
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(absolute difference of 4.5 %, 95 % CI −4.7 to 13.6 %), and
target DBP by 88.8 % (199/224) of the intervention group
and 87.9 % (189/215) of controls (absolute difference of
0.9 %, 95 % CI −5.1 to 7.1 %). Figure 2 shows the propor-
tions of patients who reached target LDL-C and SBP
values at 12 months stratified by baseline values (reaching
target or not). Among patients with above-target values at
baseline, a significantly higher proportion of the interven-
tion group showed target LDL-C values at 12 months
compared to controls (52.3 % [45/86] versus 21.3 %
[16/75]; absolute difference of 30.9 %, 95 % CI 16.1 to
43.8 %). The corresponding proportions of target SBP
values at 12 months for patients with above target at base-
line were 49.4 % (44/89) and 36.8 % (35/95) (absolute differ-
ence of 12.6 %, 95 % CI −1.7 to 26.2 %), respectively.
Figure 3 shows the proportion of patients who met
all target values (LDL-C, SBP and DBP) at baseline,
after medication titration, and at 12 months. At base-
line this proportion did not differ between the groups
(intervention 34.2 % [76/222] versus control 35.1 %
[74/211]; absolute difference of 0.8 %, 95 % CI −8.1
to 9.8 %). After medication titration, 83.8 % (186/222)
of the patients in the intervention group reached all
target values (including patients who already showed
target values at baseline) (absolute difference of
48.7 %, 95 % CI 40.1 to 56.2 %). At 12 months
40.0 % (88/220) of the intervention patients and
28.2 % (59/209) of the control patients met all target
values (absolute difference of 11.8 %, 95 % CI 2.8 to
20.5 %).
Fig. 1 Study flow diagram. *The target LDL-C value was <2.5 mmol/L until 31 March, 2013, when local guidelines for diabetic patients changed this
target to <1.8 mmol/L; †Medication was titrated until target values were reached or no further changes were considered appropriate. n: number of
cases; DM: diabetes mellitus; CKD: chronic kidney disease; LDL-C: low-density lipoprotein cholesterol; BP: blood pressure
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Sub-group analysis
Repeating the analyses separately for patients with DM
and CKD produced results that were largely similar to
the combined analyses with regard to risk factor value
differences between intervention and control patients
(see Additional files 2 and 3). The separate analyses
showed that 43.5 % (20/46) of DM patients in the inter-
vention group whose LDL-C levels were above target at
baseline had reached target LDL-C levels at 12 months,
compared to 26.5 % (9/34) in the control group (abso-
lute difference of 17.0 %, 95 % CI −4.3 to 35.6 %). The
corresponding results in the CKD group were 60.4 %
(32/53) versus 14.3 % (7/49), respectively (absolute dif-
ference of 46.1 %, 95 % CI 27.8 to 60.1 %).
Among the CKD patients in the intervention group
who showed above-target SBP at baseline, separate ana-
lysis showed that 59.6 % had reached target at
12 months, while combined DM and CKD analysis
showed a lower proportion (49.4 %). Thus, more CKD
intervention patients reached target SBP at 12 months
compared to CKD control patients (59.6 % [28/47] ver-
sus 35.2 % [19/54]; absolute difference of 24.3 %, 95 %
CI 4.9 to 41.5 %).
Discussion
The present results demonstrated that a structured, sec-
ondary preventive, nurse-based telephone follow-up of
modifiable risk factors after an ACS, stroke, or TIA led
to more prevalent LDL-C level improvement over
12 months among high-risk patients with DM or CKD
as compared to the impact of standard care. We also ob-
served a more prevalent decrease of SBP in the interven-
tion group compared to the control group, but this
difference was not statistically significant—possibly
because the patient groups were too small. A between-
group difference of 5 mmHg is probably of clinical
significance; however, the power of the study was only
sufficient to detect an 8 mmHg difference. With regard
Table 1 In-hospital patient characteristics
Intervention Control
n = 225 n = 215
Age in years, median (25th–75th
percentile)
75 (67–82) 75 (67–80)
Female, n (%) 86 (38.2) 75 (34.9)
Smoking, n (%) 25 (11.1) 23 (10.7)
BMI, median (25th–75th percentile) 27.9 (24.7–31.0) 27.2 (24.6–30.2)
Diabetes mellitus, n (%) 139 (61.8) 128 (59.5)
Chronic kidney disease, n (%) 121 (53.8) 123 (57.2)
Prior disease, n (%)
Coronary artery disease 52 (23.1) 57 (26.5)
Stroke/TIA 52 (23.1) 44 (20.5)
Peripheral artery disease 8 (3.6) 9 (4.2)
Qualifying event, n (%)
Unstable angina 7 (3.1) 9 (4.2)
NSTEMI 82 (36.4) 70 (32.6)
STEMI 30 (13.3) 24 (11.2)
TIA 35 (15.6) 42 (19.5)
Ischemic stroke 68 (30.2) 66 (30.7)
Haemorrhagic stroke 3 (1.3) 4 (1.9)
Treatment at admission, n (%)
Antihypertensive drug (≥1) 183 (81.3) 188 (87.4)
Lipid-lowering drug 92 (40.9) 113 (52.6)
Treatment at discharge, n (%)
Antihypertensive drug (≥1) 211 (93.8) 199 (92.6)
Lipid-lowering drug 185 (82.2) 180 (83.7)
n number of cases, BMI body mass index (calculated as weight in kilograms
divided by the squared height in meters), TIA transient ischemic attack,
NSTEMI non-ST elevation myocardial infarction, STEMI ST elevation
myocardial infarction
Table 2 Risk factor values for patients who had above-target values at baseline
Intervention Control p-value
LDL-C≥ 2.5/1.8a baseline, n 87 78
LDL-C baseline, median (25th–75th percentile) 2.9 (2.6–3.5) 2.9 (2.7–3.7) 0.74
LDL-C 12 months, median (25th–75th percentile) 2.2 (1.8–3.0)*** 3.0 (2.4–3.4)** <0.001
SBP≥ 140 baseline, n 89 95
SBP baseline, median (25th–75th percentile) 150 (142–160) 150 (140–160) 0.97
SBP 12 months, median (25th–75th percentile) 140 (129–155)*** 145 (130–158)*** 0.26
DBP≥ 90 baseline, n 25 26
DBP baseline, median (25th–75th percentile) 90 (90–95) 90 (90–96) 0.71
DBP 12 months, median (25th–75th percentile) 80 (75–86)*** 80 (75–91)*** 0.48
**p ≤ 0.01, ***p ≤ 0.001, indicating a significant change of median values within each group between baseline and 12 months; a The target LDL-C value was
<2.5 mmol/L until 31 March, 2013, when local guidelines for diabetic patients changed this target to <1.8 mmol/L. LDL-C low-density lipoprotein cholesterol
(mmol/L), n number of cases, SBP systolic blood pressure (mmHg), DBP diastolic blood pressure (mmHg)
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to the proportion of patients reaching target values, the
examined intervention was significantly more effective
concerning LDL-C, and showed a trend of being more
effective for SBP.
Previous population-based studies have shown that
approximately 15–60 % of participants reach target
values for LDL-C or BP [5–7]. In the present study, as
many as 83.8 % of the patients in the intervention group
reached the target LDL-C, SBP, and DBP values after
medication titration (Fig. 3). At 12 months, the propor-
tion of participants with target values had decreased to
40 %. Similarly, a fairly large proportion of the patients
with target levels at baseline showed above-target values
at 12 months. This might be explained by decreased
medication adherence over time. More frequent follow-
ups during the first year are probably beneficial, but our
present findings indicate that secondary prevention
efforts should extend beyond 12 months of follow-up.
The NAILED trials are planned to follow-up patients for
a minimum of 36 months [17, 18].
Our results are in agreement with a previous meta-
analysis of 11 studies, which found that telehealth inter-
ventions (phone and internet communication between
patient and healthcare providers) effectively reduced risk
factors among patients with coronary heart disease [10].
The meta-analysis showed that intervention decreased
the weighted mean difference for LDL-C by 0.41 mmol/
L and for SBP by 4.69 mmHg. This can be compared to
the presently observed median decrease of 0.8 mmol/L
in LDL-C and of 5 mmHg in SBP. The present study
showed a larger risk factor reduction, even though the
median patient age was 75 years compared to the mean
age of 57–64 years in the meta-analysis [10]. The age of
the NAILED study population is more representative of
the general ACS, stroke, and TIA population than the
younger patients included in previous trials evaluating
telephone-supported secondary preventive follow-up.
We believe that prompt medication titration and
follow-up every four weeks until target values are reached
represent a key component of the NAILED method.
Two recently published Cochrane reviews evaluate
organizational strategies to improve risk factor control
after a CVD, and report only weak effects or no effect on
modifiable risk factor levels. None of the included studies
that are available in English used a method involving
prompt medication titration [8, 9]. In the PREVENTION
study, prompt medication titration performed by pharma-
cists authorized to prescribe medication resulted in
increased proportions of patients reaching the desired risk
factor levels [21].
Our separate analyses of DM or CKD patients showed
that the CKD patients seemed to gain more from the
NAILED intervention. This may be partly explained by the
fact that DM patients are carefully monitored within the
Swedish healthcare system. In the county of Jamtland, DM
patients have a standard yearly visit to the GP and a
yearly visit to a nurse for evaluation of the patients’
diabetes-associated problems, such as BP and LDL.
Consequently, their risk factors are typically better
monitored compared to the general CVD population.
The greater benefit seen in the intervention patients
with CKD may also be due to the concerns that GPs have
regarding medication usage in patients with decreased
kidney function, which may make them hesitant to inten-
sify treatment. A meta-analysis investigating statin treat-
ment in CKD patients reported that statins had beneficial
effects on mortality and cardiovascular events in pre-
dialysis CKD patients, without increased adverse effects
Fig. 2 Proportion of patients who reached target values at
12 months, stratified by whether the patients were within or
above target values at baseline. *The target LDL-C value was
<2.5 mmol/L until 31 March 2013, when local guidelines for
diabetic patients changed this target to <1.8 mmol/L. SBP:
systolic blood pressure; LDL-C: low-density lipoprotein cholesterol
Fig. 3 Proportion of patients reaching target LDL-C, SBP and DBP.
*The proportion reported for control patients is the same as at
baseline since control patients did not receive any medication
titration within the study period
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[22]. Patients with terminal disease were not included in
the NAILED trials. Thus, it is unclear why 85.7 % of the
control CKD patients who were above target LDL-C levels
at baseline were still above target at 12 months.
Limitations
The method used in the NAILED trial was designed to be
broadly implementable in clinical practice and, therefore,
all patients were considered for inclusion if they were able
to participate and were not enrolled in a concurrent trial.
A patient’s ability to participate was assessed by a study
nurse, introducing a risk of arbitrariness in the decision of
eligibility. Another potential weakness was the BP meas-
urement procedure, which was performed by a large num-
ber of healthcare professionals at different healthcare
centres in the county and using different devices. The let-
ter of referral included simple instructions for what was
considered a standardized BP measurement [17, 18], but
the accuracy of the individual BP measurements could
have varied. However, this should not be a major concern,
since it is reasonable to believe that any inaccuracy would
have been fairly equally distributed between the two study
groups. Finally, we defined CKD according to an estimate
from a single creatinine value. This differs from the
recommended definition of CKD, which requires two
measurements taken three months apart [20].
Conclusion
Our present results showed that nurse-based telephone
follow-up including medication titration was more effect-
ive than usual care for reducing LDL-C levels and increas-
ing the proportion of patients showing target LDL-C
values at 12 months after an ACS, stroke, or TIA among
high-risk patients with DM or CKD. The corresponding
decrease in SBP and increase in the proportion of patients
with target SBP values at 12 months did not significantly
differ from those seen in patients with usual care.
The results support our hypothesis that the NAILED
follow-up is more efficient than usual care to reduce
levels of modifiable risk factors after a CVD in patients
with DM or CKD. Future reports will reveal whether
nurse-based telephone follow-up is more effective than
usual care to achieve long-term risk factor control.
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